Inalpin may be available in the countries listed below.
Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Inalpin in the following countries:
Guaifenesin is reported as an ingredient of Inalpin in the following countries:
International Drug Name Search
Rem Chobet may be available in the countries listed below.
Midazolam is reported as an ingredient of Rem Chobet in the following countries:
International Drug Name Search
Aratan-D may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Aratan-D in the following countries:
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Aratan-D in the following countries:
International Drug Name Search
Caprimida may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Caprimida in the following countries:
International Drug Name Search
K&P Hydrocortison may be available in the countries listed below.
Hydrocortisone is reported as an ingredient of K&P Hydrocortison in the following countries:
International Drug Name Search
Generic Name: acetaminophen/brompheniramine/phenylpropanolamine (a see ta MIH noe fen/brome feh NEER a meen/fen ill proe pa NOLE a meen)
Brand Names: Dimetapp Allergy Sinus, Dimetapp Cold and Flu
Acetaminophen is a pain reliever and a fever reducer. It is used to treat many conditions, such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers.
Brompheniramine is an antihistamine. It blocks the effects of the naturally occurring chemical histamine in the body. Brompheniramine prevents sneezing; itchy, watery eyes and nose; and other symptoms of allergies and hay fever.
Phenylpropanolamine is a decongestant. It constricts (shrinks) blood vessels (veins and arteries). This reduces the blood flow to certain areas, which allows nasal passages to open up.
Acetaminophen/brompheniramine/phenylpropanolamine is used to treat nasal congestion; itchy, watery eyes; itchy throat; sneezing; headache; fever; and other symptoms associated with allergies, hay fever, and the common cold.
Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.
Acetaminophen/brompheniramine/phenylpropanolamine may also be used for purposes other than those listed in this medication guide.
Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.
Before taking this medication, tell your doctor if you have
diabetes,
glaucoma,
any type of heart disease or high blood pressure,
thyroid disease,
emphysema or chronic bronchitis, or
difficulty urinating or have an enlarged prostate.
You may not be able to take acetaminophen/brompheniramine/phenylpropanolamine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.
Take acetaminophen/brompheniramine/phenylpropanolamine exactly as directed. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
To ensure that you get a correct dose, measure the liquid forms of acetaminophen/brompheniramine/phenylpropanolamine with a special dose-measuring spoon or cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist where you can get one.
Do not take acetaminophen/brompheniramine/phenylpropanolamine for longer than 7 to 10 days in a row. If your symptoms do not improve, if they get worse, or if you have a fever, see your doctor.
Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication.
Symptoms of an acetaminophen/brompheniramine/phenylpropanolamine overdose include a dry mouth, large pupils, flushing, nausea, vomiting, abdominal pain, diarrhea, seizures, confusion, sweating, and an irregular heartbeat.
Acetaminophen/brompheniramine/phenylpropanolamine may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, other antihistamines, pain relievers, anxiety medicines, seizure medicines, and muscle relaxants. Dangerous sedation, dizziness, or drowsiness may occur if acetaminophen/brompheniramine/phenylpropanolamine is taken with any of these medications.
an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
liver damage (yellowing of the skin or eyes, nausea, abdominal pain or discomfort, unusual bleeding or bruising, or severe fatigue);
blood problems (easy or unusual bleeding or bruising); or
low blood sugar (fatigue, increased hunger or thirst, dizziness, or fainting).
Other, less serious side effects may be more likely to occur including:
dryness of the eyes, nose, and mouth;
drowsiness or dizziness;
blurred vision;
difficulty urinating; or
excitation in children.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
Urine glucose tests for diabetics may produce false results while taking acetaminophen. Talk to your doctor if you have diabetes and you notice changes in blood glucose levels during therapy with acetaminophen/brompheniramine/phenylpropanolamine.
Do not take other over-the-counter cough, cold, allergy, diet, pain, or sleep medicines while taking acetaminophen/brompheniramine/phenylpropanolamine without first talking to your doctor or pharmacist. Other medications may also contain brompheniramine, phenylpropanolamine, acetaminophen, or other similar drugs, and you may accidentally take too much of these medicines.
Acetaminophen/brompheniramine/phenylpropanolamine may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, other antihistamines, pain relievers, anxiety medicines, seizure medicines, and muscle relaxants. Dangerous sedation, dizziness, or drowsiness may occur if acetaminophen/brompheniramine/phenylpropanolamine is taken with any of these medications.
Drugs other than those listed here may also interact with acetaminophen/brompheniramine/phenylpropanolamine. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
Acetaminophen/brompheniramine/phenylpropanolamine is available over-the-counter under the brand names Dimetapp Cold and Flu and Dimetapp Allergy Sinus. Other brand or generic formulations may also be available. Ask your pharmacist any questions you have about this medication, especially if it is new to you.
Cefacher may be available in the countries listed below.
Cefalexin is reported as an ingredient of Cefacher in the following countries:
International Drug Name Search
Mitem may be available in the countries listed below.
Mitomycin is reported as an ingredient of Mitem in the following countries:
International Drug Name Search
Neo Kaocitin may be available in the countries listed below.
Kaolin is reported as an ingredient of Neo Kaocitin in the following countries:
Pectin is reported as an ingredient of Neo Kaocitin in the following countries:
International Drug Name Search
Gentamicina + Betametasone ABC may be available in the countries listed below.
Betamethasone 17α-valerate (a derivative of Betamethasone) is reported as an ingredient of Gentamicina + Betametasone ABC in the following countries:
Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Gentamicina + Betametasone ABC in the following countries:
International Drug Name Search
Sulfapyrine LA may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfamethoxypyridazine is reported as an ingredient of Sulfapyrine LA in the following countries:
International Drug Name Search
Evital may be available in the countries listed below.
Levonorgestrel is reported as an ingredient of Evital in the following countries:
International Drug Name Search
RE Iron Tablets 90mg is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias.
One tablet daily or as directed by a physician.
RE Iron Tablets 90mg is contraindicated in patients with known hypersensitivity to any of its ingredients. Folic acid (pteroylglutamic acid) is contraindicated in patients with untreated and uncomplicated pernicious anemia and in those with anaphylactic sensitivity to folic acid. Iron therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron stage disease dude to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc.) pyridoxine responsive anemia or cirrhosis of the liver.
Allergic sensitivity reactions and gastrointestinal disturbances may occur with iron therapy. Folic Acid allergic sensitization has been reported following both oral and parenteral administration.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
There is a variety of iron/drug interactions which include antacids, tetracyclines, or fluoroquinolones.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Geriatric Use: clinical studies on this product have not been performed in sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects,. In general, dose selection for an elderly patient should be made cautiously, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
The clinical course of acute iron overdosage can vary. Initial symptoms may include abdominal pain, nausea, vomiting, diarrhea, tarry stools, melena, hematemesis, hypotension, tachycardia, metabolic acidosis, hyperglycemia, dehydration, drowsiness, pallor, cyanosis, lassitude, seizures, shock and coma.
Iron is necessary for the proper functioning of hemoglobin and red blood cell production.
Folic acid is required for cell division and growth and the maintenance of red blood cells.
Vitamin B12 is required for the maintenance of normal red blood cell synthesis, cell reproduction and normal growth. Intrinsic factor, a gastric protein secreted by the parietal cells, is required for the absorption of Vitamin B12 from the gastrointestinal tract.
Pernicious anemia should be ruled out before starting treatment. While folic acid corrects the hematological profile or pernicious anemia, it does not ameliorate the underlying neurologic involvement.
RE Iron Tablets 90 mg (NDC 68032-371-90) is a reddish-brown, modified rectangle shaped, film-coated tablet, debossed with “RE 371” on one side and blank on the other, and packaged in bottles of 90.
Store at 25C (77F). Excursions permitted to 15-30C (59-86F). (See USP Controlled Room Temperature.)
NOTICE: Contact with moisture can discolor or erode the tablet. Do not chew tablet.
| IRON iron pentacarbonyl tablet | ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| unapproved drug other | 04/01/2009 | 06/30/2011 | |
| Labeler - River's Edge Pharmaceuticals, LLC (133879135) |
Hepaderm may be available in the countries listed below.
Sodium Alginate Sulfate is reported as an ingredient of Hepaderm in the following countries:
International Drug Name Search
Medamarin may be available in the countries listed below.
Lansoprazole is reported as an ingredient of Medamarin in the following countries:
International Drug Name Search
Gen-Amantadine may be available in the countries listed below.
Amantadine hydrochloride (a derivative of Amantadine) is reported as an ingredient of Gen-Amantadine in the following countries:
International Drug Name Search
Cambia is a brand name of diclofenac, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Cambia available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cambia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Grifonimod may be available in the countries listed below.
Nimodipine is reported as an ingredient of Grifonimod in the following countries:
International Drug Name Search
Generic Name: guaifenesin and phenylpropanolamine (gwye FEN e sin/fen ill proe pa NOLE a meen)
Brand Names: Ami-Tex LA, Banex-LA, Coldloc-LA, Dayquil Sinus Pressure and Congestion, Despec, Entex LA, Exgest LA, G-Vent, Guaifenex PPA 75, Guaivent, Guiatex LA, Naldecon-EX Pediatric, Nasahist LA, Phentex-LA, Phenylfenesin LA, Poly-Vent, Profen LA, Stamoist LA, Triaminic Expectorant, Vanex-LA
Guaifenesin is an expectorant. It is used to break up congestion and mucous to make breathing easier. Guaifenesin thins mucous, increases lubrication of the respiratory tract (lungs, nose and throat), and increases the removal of mucous.
Phenylpropanolamine is a decongestant. It constricts (shrinks) blood vessels (veins and arteries), which reduces swelling of mucous membranes in areas such as the nose and sinuses.
Guaifenesin and phenylpropanolamine is used to treat the symptoms of the common cold and of infections of the sinuses, lungs, and throat.
Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.
Guaifenesin and phenylpropanolamine may also be used for purposes other than those listed in this medication guide.
Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.
Before taking this medication, tell your doctor if you have
high blood pressure or any other type of heart disease,
diabetes,
a peripheral vascular disorder (poor circulation),
glaucoma or increased pressure in the eyes,
an overactive thyroid, or
difficulty urinating or an enlarged prostate.
You may not be able to take guaifenesin and phenylpropanolamine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.
Take guaifenesin and phenylpropanolamine exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication.
Symptoms of a guaifenesin and phenylpropanolamine overdose include vomiting, high blood pressure (headache, redness of face, blurred vision), an irregular heartbeat, and numbness of the fingers or toes.
Other, less serious side effects may be more likely to occur. Continue to take guaifenesin and phenylpropanolamine and talk to your doctor if you experience
dizziness or headache;
nervousness, restlessness, or insomnia;
nausea or stomach upset; or
difficulty urinating.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
Heart medications such as methyldopa (Aldomet), reserpine (Serpalan, Serpasil), and guanethidine (Ismelin) may have decreased effects. Talk to your doctor before taking guaifenesin and phenylpropanolamine if you are taking any of these medications.
Do not take other over-the-counter cough, cold, allergy, diet, or sleep aids while taking guaifenesin and phenylpropanolamine without first talking to your doctor or pharmacist. Other medications may also contain guaifenesin, phenylpropanolamine, or other similar drugs. You may accidentally take too much of these medicines.
Drugs other than those listed here may also interact with guaifenesin and phenylpropanolamine. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
Guaifenesin and phenylpropanolamine is available with a prescription under several brand names. Ask your pharmacist any questions you have about this medication, especially if it is new to you.
Entex LA, 400 mg of guaifenesin and 75 mg of phenylpropanolamine--orange, scored tablets
Exgest LA, 400 mg of guaifenesin and 75 mg of phenylpropanolamine--white, oval-shaped, scored, long-acting tablets with blue speckles
Dura-Vent, 600 mg of guaifenesin and 75 mg of phenylpropanolamine--white, scored tablets
See also: Banex-LA side effects (in more detail)
Girolac may be available in the countries listed below.
Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Girolac in the following countries:
International Drug Name Search
Easy to administer.
For the removal of large roundworms (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala) in dogs and puppies. The presence of these parasites should be confirmed by laboratory fecal exam. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism.
RFD Liquid Wormer may also be used to prevent reinfestation of T. canis in puppies and adult dogs and in lactating bitches after whelping.
Shake Well Before Use
Active Ingredient: 2.27 mg of pyrantel base as pyrantel pamoate per mL.
Store below 30°C (86°F).
Keep out of reach of children.
Administer 1 teaspoon (5 mL) for each 5 lb of body weight. To assure proper dosage, weigh animal prior to treatment. It is not necessary to withhold food prior to treatment. Dogs usually find this dewormer very palatable and will lick the dose from the bowl willingly. If there is reluctance to accept the dose, mix in a small quantity of dog food to encourage consumption. It is recommended that dogs maintained under conditions of constant exposure to worm infestation should have a follow-up fecal exam within 2–4 weeks after first treatment. If your dog looks or acts sick, consult your veterinarian before treatment.
For maximum control and prevention of reinfestation, it is recommended that puppies be treated at 2, 3, 4, 6, 8 and 10 weeks of age. Lactating bitches should be treated 2–3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals to prevent T. canis reinfestation.
Distributed by:
Pfizer Animal Health
Div. of Pfizer Inc, NY, NY 10017
7985000
10229200
81551791
81607983, R.0
Made in USA
RFD®
(pyrantel pamoate)
LIQUID
WORMER
FOR PUPPIES AND DOGS
NADA #100-237, APPROVED BY FDA
Net Contents:
2 fl oz (60 mL)
Pfizer
| RFD WORMER pyrantel pamoate suspension | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NADA | NADA100237 | 06/03/1979 | |
| Labeler - Pfizer Animal Health (039055157) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Pfizer Animal Health | 039055157 | MANUFACTURE | |
Zadorin may be available in the countries listed below.
Doxycycline hyclate (a derivative of Doxycycline) is reported as an ingredient of Zadorin in the following countries:
Doxycycline hydrochloride (a derivative of Doxycycline) is reported as an ingredient of Zadorin in the following countries:
International Drug Name Search
Bovaclox may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Bovaclox in the following countries:
Cloxacillin benzathine (a derivative of Cloxacillin) is reported as an ingredient of Bovaclox in the following countries:
International Drug Name Search
Micotef may be available in the countries listed below.
Miconazole is reported as an ingredient of Micotef in the following countries:
Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Micotef in the following countries:
International Drug Name Search
Generic Name: betamethasone topical (bay ta METH a sone)
Brand names: Alphatrex, Beta-Val, Diprolene, Diprolene AF, Diprosone, Luxiq, ...show all 14 brand names.
Betamethasone is a topical steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.
Betamethasone topical is used to treat the inflammation caused by a number of conditions such as allergic reactions, eczema, and psoriasis. The dental paste form of betamethasone is used to treat mouth ulcers.
Betamethasone topical may also be used for other purposes not listed in this medication guide.
Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended.
Avoid using this medication on your face, near your eyes, or on body areas where you have skin folds or thin skin.
Betamethasone topical will not treat a bacterial, fungal, or viral skin infection.
Before using betamethasone topical, tell your doctor if you are allergic to any drugs, or if you have any type of skin infection.
Use this medication exactly as it was prescribed for you. Do not use the medication in larger amounts, or use it for longer than recommended by your doctor. Follow the instructions on your prescription label.
Betamethasone topical will not treat a bacterial, fungal, or viral skin infection.
Wash your hands before and after each application, unless you are using betamethasone topical to treat a hand condition.
Apply a small amount to the affected area and rub it gently into the skin.
Avoid using this medication on your face, near your eyes or mouth, or on body areas where you have skin folds or thin skin.
If you are using the dental paste, apply the medication in a thin layer, just enough to cover the mouth ulcer. The paste may stick better if you dry the mouth ulcer before applying the medication.
Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and use the medicine at the next regularly scheduled time. Do not use extra medicine to make up the missed dose.
Avoid using skin products that can cause irritation, such as harsh soaps or shampoos or skin cleansers, hair coloring or permanent chemicals, hair removers or waxes, or skin products with alcohol, spices, astringents, or lime. Do not use other medicated skin products unless your doctor has told you to.
blurred vision, or seeing halos around lights;
uneven heartbeats;
mood changes;
sleep problems (insomnia);
weight gain, puffiness in your face; or
feeling tired.
Less serious side effects may include:
skin redness, burning, itching, or peeling;
thinning of your skin; or
blistering skin; or
stretch marks.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Dermatitis:
Topical: Apply a thin film to the affected area 1-3 times a day.
Foam: Apply twice daily (in morning and at night).
Usual Pediatric Dose for Dermatitis:
Cream, ointment and lotion:
>=13 years: Apply a thin film to the affected area 1-3 times a day.
It is not likely that other drugs you take orally or inject will have an effect on topically applied betamethasone topical. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
Alerid may be available in the countries listed below.
Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Alerid in the following countries:
International Drug Name Search
Scanalgin may be available in the countries listed below.
Metamizole is reported as an ingredient of Scanalgin in the following countries:
International Drug Name Search
Trafloxal may be available in the countries listed below.
Ofloxacin is reported as an ingredient of Trafloxal in the following countries:
International Drug Name Search
Morfina cloridrato Salf may be available in the countries listed below.
Morphine hydrochloride (a derivative of Morphine) is reported as an ingredient of Morfina cloridrato Salf in the following countries:
International Drug Name Search
See also: Generic Isovue-200, Generic Isovue-300, Generic Isovue-370
Isovue-250 is a brand name of iopamidol, approved by the FDA in the following formulation(s):
Yes. The following products are equivalent to Isovue-250:
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Isovue-250. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Isovue-250.
Amoxicillin AL may be available in the countries listed below.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxicillin AL in the following countries:
International Drug Name Search
Afun may be available in the countries listed below.
Clotrimazole is reported as an ingredient of Afun in the following countries:
International Drug Name Search
Mepacrine Hydrochloride may be available in the countries listed below.
Mepacrine Hydrochloride (BANM) is also known as Mepacrine (Rec.INN)
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Quark may be available in the countries listed below.
Ramipril is reported as an ingredient of Quark in the following countries:
International Drug Name Search
Contine may be available in the countries listed below.
Theobromine Sodium Salicylate is reported as an ingredient of Contine in the following countries:
International Drug Name Search
Treating acne. It may also be used for other conditions as determined by your doctor.
Benzoyl Peroxide/Sulfur Gel is a keratolytic agent with antibacterial actions. Exactly how Benzoyl Peroxide/Sulfur Gel works to treat acne is unknown, but it may be effective because of its antibacterial, peeling (keratolytic), and drying actions.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Benzoyl Peroxide/Sulfur Gel. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Benzoyl Peroxide/Sulfur Gel. However, no specific interactions with Benzoyl Peroxide/Sulfur Gel are known at this time.
This may not be a complete list of all interactions that may occur. Ask your health care provider if Benzoyl Peroxide/Sulfur Gel may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Benzoyl Peroxide/Sulfur Gel as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Benzoyl Peroxide/Sulfur Gel.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Dryness; peeling; redness; stinging.
Severe allergic reactions (rash; hives; itching; dizziness; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); excessive burning, itching, irritation, peeling, redness, or tenderness of your skin; extreme dryness; swelling.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Benzoyl Peroxide/Sulfur side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include excessive scaling; flushing; redness; swelling.
Store at room temperature between 59 and 86 degrees F (15 and 30 degrees C). Store in a tightly closed container. Store away from fire, flame, heat, and light. Keep Benzoyl Peroxide/Sulfur Gel out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Benzoyl Peroxide/Sulfur Gel. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Salbutamol WZF may be available in the countries listed below.
Salbutamol is reported as an ingredient of Salbutamol WZF in the following countries:
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Salbutamol WZF in the following countries:
International Drug Name Search
Class: beta-Adrenergic Blocking Agents
ATC Class: S01ED52
VA Class: OP101
Molecular Formula: C18H29NO3•ClH
CAS Number: 63659-19-8
Brands: Betoptic S
β1-selective adrenergic blocking agent.1 2 3 4 5 6 7 8 9 10 121 122
Reduction of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma1 2 8 12 18 19 20 74 93 94 121 a b 122 and ocular hypertension.1 2 9 10 11 94 a b Used alone or in conjunction wth a topical miotic121 122 (e.g., pilocarpine),1 2 12 18 122 topical dipivefrin,1 2 99 122 topical epinephrine, 1 12 18 74 98 121 122 and/or a carbonic anhydrase inhibitor.1 2 10 12 121 122
May be used safely in selected patients with reactive airway disease (e.g., asthma, chronic bronchitis, COPD).1 2 20 21 30 97 (See Respiratory Effects under Cautions.)
Adjust dosage to individual requirements and response of patient as determined by tonometric readings before and during therapy.1 65
Because of diurnal variations in IOP, measure IOP at different times during the day to determine if an adequate hypotensive effect is maintained.107 Since IOP may not stabilize for a few weeks after initiating therapy, determine IOP after about 4 weeks of therapy; thereafter, determine IOP as necessary.1
Apply topically to the eye as an ophthalmic solutionb or suspensiona .
Avoid contamination of the solution or suspension container.1 103 121 a b
Shake suspension well prior to use.121 122
Suspension should not be administered while wearing contact lenses.121
Available as betaxolol hydrochloride; dosage expressed in terms of betaxolol.a
Suspension is therapeutically equivalent (in terms of magnitude and duration of hypotensive effect) to solution.121 122 126
Each 2.8 or 5.6 mg of betaxolol hydrochloride is equivalent to about 2.5 or 5 mg of betaxolol, respectively.1 2 121 a b
Betaxolol solution: 1–2 drops of a 0.5% solution in affected eye(s) twice daily. b 8 2 121 122
Betaxolol suspension: 1–2 drops of a 0.25% suspension in affected eye(s) twice daily. 1 a 8 2 121 122
If further reduction of IOP is required, a topical miotic,1 2 18 74 121 topical dipivefrin,2 12 99 122 topical epinephrine,1 12 18 74 98 121 122 and/or a carbonic anhydrase inhibitor1 2 10 12 121 122 may be added.1 2 10 12 74 121 122
Known hypersensitivity to betaxolol or any ingredient in the formulation.a b
Sinus bradycardia,1 18 121 a b AV block greater than first degree,1 18 121 cardiogenic shock,1 18 121 or overt cardiac failure 1 121 that is not adequately compensated (e.g., with cardiac glycosides and/or diuretics).104
May be absorbed systemically following topical application to the eye; consider the usual precautions associated with systemic use of β-adrenergic blocking agents when using topical betaxolol.1 119 121 a
Severe cardiac reactions, including death associated with cardiac failure, have been reported in patients receiving topical (ocular) betaxolol.a b
Minor effects on BP 1 2 8 9 22 23 93 110 121 122 and heart rate reported.1 2 8 9 22 23 93 110
Use with caution in patients with a history of cardiac failure or heart block.1 119 121 Discontinue therapy at the first sign or symptom of cardiac failure.1 119 121
Severe respiratory reactions, including death resulting from bronchospasm, have been reported in patients with asthma receiving topical (ocular) betaxolol.1 2
Increased airway resistance and pulmonary distress (i.e., dyspnea, bronchospasm, thickened bronchial secretions, asthma, respiratory failure) reported.1 21 95 121 122 Use caution in patients with evidence of reactive airway disease on pulmonary function testing or excessive restriction of pulmonary function.1 113 121 122
Possible increased reactivity to repeated accidental, diagnostic, or therapeutic challenges with a variety of allergens while taking β-adrenergic blocking agents.a b Such patients may be unresponsive to usual doses of epinephrine used to treat anaphylactic reactions.a b
β-Adrenergic blocking agents may mask sings and symptoms of acute hypoglycemia; administer with caution in patients subject to spontaneous hypoglycemia and in diabetic patients (especially those with labile diabetes) who are receiving hypoglycemic agents.1 88 121
β-Adrenergic blocking agents may mask signs of hyperthyroidism (e.g., tachycardia).1 121
Possible thyroid storm if β-adrenergic blocking agent is abruptly withdrawn; carefully monitor patients having or suspected of developing thyrotoxicosis.1 121
β-Adrenergic blocking agents reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, generalized weakness).1 121
Betaxolol reported rarely to increase muscle weakness in patients with myasthenia gravis or myasthenia symptoms.a b
Possible increased risks associated with general anesthesia (e.g., severe hypotension, difficulty restarting or maintaining heart beat) due to decreased ability of the heart to respond to reflex β-adrenergic stimuli.1 121 Some clinicians recommend gradual withdrawal of β-adrenergic blocking agents prior to elective surgery.1 121
Betaxolol has little to no effect on pupil size.1 2 8 9 11 12 18 93 99 121 122 Do not use alone in patients with angle-closure glaucoma; use only in combination with a miotic in these patients.1 121
Category C.a b
Distributed into milk.83 Caution advised if used in nursing women.1 121
Safety and efficacy not established.1 11 121
No substantial differences in safety and efficacy relative to younger adults.a
Ocular stinging and discomfort on instillation.1 2 8 18 74 94 98 121 122 126
Drug | Interaction | Comments |
|---|---|---|
Adrenergic psychotropic agents | Possible antagonism of psychotropic agenta b | Use concomitantly with cautiona b |
Catecholamine-depleting drugs (e.g., reserpine) | Possible additive effectsa b | Observe closely for evidence of marked hypotension or bradycardiaa b |
Ocular hypotensive agents | Additive IOP-lowering effectsa b | Used to therapeutic advantagea b Observe for additive effect of IOP reduction or systemic side effectsa b |
Systemic β-adrenergic blocking agents | Additive systemic and ocular effectsa b |
Extent of absorption following topical application not elucidated.104
Commercially available solution and suspension are bioequivalent.122 126
Following topical application to the eye with either the 0.25% suspension or the 0.5% solution, reduction in IOP usually evident within 0.5–1 hour and reaches a maximum within 2 hours.1 2 121
Reduction in IOP persists for ≥12 hours.1 2 121
Distribution into human ocular tissues and fluids has not been characterized to date.104
Betaxolol crosses the placenta and is distributed into milk.83 108
Systemically absorbed betaxolol is extensively metabolized to at least 5 metabolites.2 13 46
Tight containers at 15–30°C.b
Upright at 15–30°C.a
Selective β1-adrenergic blocking agenta b 1 2 3 4 5 6 7 8 9 10 13 16 17 25 45 48 83 121 122 that does not exhibit intrinsic β1-agonist or membrane stabilizing (local anesthetic) activity.1 2 8 9 13 18 25 28 83 121 122
One of the most potent2 6 13 16 17 25 45 48 122 and selective2 13 16 17 25 48 122 β1-adrenergic blocking agents currently available.
Reduces both elevated1 2 8 9 11 12 14 19 93 94 121 122 and normal1 2 7 IOP8 9 10 11 14 19 93 94 121 without affecting pupillary size1 2 8 9 11 12 18 93 94 99 122 or accommodation2 8 9 11 122 and without producing miosis and/or ciliary spasm associated with miotic agents.1 2 8 9 11 12 18
Reduces IOP by about 20–35% from baseline in patients with elevated IOP.a b 1 8 9 11 122
Exact mechanism of action not fully elucidated; tonography and fluorophotometric studies suggest that reduced aqueous humor formation is the principal effect. a b 1 2 8 9 11 12 18 93 122
May block endogenous catecholamine-stimulated increases in cyclic adenosine monophosphate (AMP) concentrations within the ciliary processes and subsequent formation of aqueous humor.64 65 115 116 117 118
Does not appear to affect aqueous outflow resistance.7 19
Tolerance may develop with prolonged use;1 however, IOP-lowering effect maintained for ≥4 years of continuous use in some patients.2 104
Importance of learning and adhering to proper administration techniques to avoid contamination of the product.a
Importance of not using suspension while having contact lenses in eyes.a
Advise patients to consult a clinician immediately regarding continued use of ophthalmic preparations if an intercurrent ocular condition (e.g., trauma, infection) occurs.
Importance of patients informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.a
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a
Importance of informing patients of other important precautionary information. a (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Ophthalmic | Solution | 0.5% (of betaxolol)* | Betaxolol Hydrochloride Ophthalmic Solution | Akorn, Apotex, Bausch & Lomb, Falcon |
Suspension | 0.25% (of betaxolol) | Betoptic S (with benzalkonium chloride) | Alcon |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Betaxolol HCl 0.5% Solution (FALCON PHARMACEUTICALS): 15/$120 or 30/$235.98
Betoptic-S 0.25% Suspension (ALCON VISION): 15/$193.99 or 45/$568.98
Betoptic-S 0.25% Suspension (ALCON VISION): 10/$133.99 or 30/$378.97
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions May 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Alcon Laboratories. Betoptic (betaxolol hydrochloride) solution prescribing information. Ft. Worth, TX; 1991 Feb.
2. Alcon Laboratories. Betoptic product monograph. Ft. Worth, TX; 1985 Sep.
3. Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:181-214.
4. Windholz M, ed. The Merck index. 10th ed. Rahway, NJ: Merck & Co, Inc; 1983:169.
5. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 28th ed. London: The Pharmaceutical Press; 1982:1684.
6. Manoury P. Betaxolol: chemistry and biological profile in relation to its physicochemical properties. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:13-9.
7. Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology. 1983; 90:1369-72. [PubMed 6664677]
8. Berrospi R, Leibowitz HM. Betaxolol: a new β-adrenergic blocking agent for treatment of glaucoma. Arch Ophthalmol. 1982; 100:943-6. [IDIS 151861] [PubMed 6124227]
9. Caldwell DR, Salisbury CR, Guzek JP. Effects of topical betaxolol in ocular hypertensive patients. Arch Ophthalmol. 1984; 102:539-40. [IDIS 183932] [PubMed 6704008]
10. Smith JP, Weeks RH, Newland EF et al. Betaxolol and acetazolamide: combined ocular hypotensive effect. Arch Ophthalmol. 1984; 102:1794-5. [IDIS 192616] [PubMed 6391442]
11. Radius RL. Use of betaxolol in the reduction of elevated intraocular pressure. Arch Ophthalmol. 1983; 101:898-900. [IDIS 171713] [PubMed 6860201]
12. Levy NS, Boone L, Ellis E. A controlled comparison of betaxolol and timolol with long-term evaluation of safety and efficacy. Glaucoma. 1985; 7:54-62.
13. Cavero I, Lefèevre-Borg F, Manoury P et al. In vitro and in vivo pharmacological evaluation of betaxolol, a new, potent, and selective β1-adrenoceptor antagonist. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:31-42.
14. Levy NS, Boone L. Effect of 0.25% betaxolol v placebo. Glaucoma. 1983; 5:230-2.
15. Vareilles P, Silverstone D, Plazonnet B et al. Comparison of the effects of timolol and other adrenergic agents on intraocular pressure in the rabbit. Invest Ophthalmol Vis Sci. 1977; 16:987-96. [PubMed 21145]
16. Shanks RG. Comparison of betaxolol with other β-blocking drugs in healthy volunteers. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:133-41.
17. Cadigan PJ, London D, Pentecost BL. Effects of betaxolol, given in single doses by mouth, on pulse rate and blood pressure in normal subjects. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:101-7.
18. Berry DP Jr, Van Buskirk EM, Shields MB. Betaxolol and timolol: a comparison of efficacy and side effects. Arch Ophthalmol. 1984; 102:42-5. [IDIS 180348] [PubMed 6367723]
19. Allen RC, Epstein DL. A double-masked clinical trial of betaxolol and timolol in glaucoma patients. Invest Ophthalmol Vis Sci. 1982; 22(Suppl):40.
20. Allen RC, Boys-Smith J. Betaxolol in patients with coexistant glaucoma and pulmonary disease. Invest Ophthalmol Vis Sci. 1984; 25(Suppl 3):305.
21. Schoene RB, Abuan T, Ward RL et al. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol. 1984; 97:86-92. [IDIS 180609] [PubMed 6141730]
22. Atkins JM, Pugh BR Jr, Timewell RM. Cardiovascular effects of topical beta-blockers during exercise. Am J Ophthalmol. 1985; 99:173-5. [IDIS 205613] [PubMed 3970121]
23. Hernandez y Hernandez H, Cervantes R, Frati A et al. Cardiovascular effects of topical glaucoma therapies in normal subjects. J Toxicol Cutaneous Ocul Toxicol. 1983; 2:99-106.
24. Bloom E, Richmond C, Alvarado J et al. Betaxolol vs. timolol: plasma radio-receptor assays to evaluate systemic complications of beta blocker therapy for glaucoma. Invest Ophthalmol. 1985; 26(Suppl):125.
25. Boudot JP, Cavero I, Féenard S et al. Preliminary studies on SL 75212, a new potent cardioselective β-adrenoceptor antagonist. Br J Pharmacol. 1979; 66:445P. [PubMed 43176]
26. Kilborn JR, Morselli PL, Saunders J et al. The effects of the new β-adrenoceptor blocker SL 75212 on the cardiovascular responses to insulin induced hypoglycaemia in man. Br J Clin Pharmacol. 1979; 8:409P. [IDIS 105845] [PubMed 41561]
27. Davis BJ, Turner P. The spectrofluorimetric estimation and buccal absorption of SL 75212, a novel β-adrenoceptor antagonist. Br J Clin Pharmacol. 1979; 8:405P. [IDIS 105840] [PubMed 41558]
28. Cadigan PJ, London DR, Pentecost BL et al. Cardiovascular effects of single oral doses of the new β-adrenoceptor blocking agent betaxolol (SL 75212) in healthy volunteers. Br J Clin Pharmacol. 1980; 9:569-75. [IDIS 115944] [PubMed 6104498]
29. Salonen JT, Palminteri R. Comparison of two doses of betaxolol and placebo in hypertension: a randomized, double-blind cross-over trial. Eur J Clin Pharmacol. 1982; 23:491-4. [IDIS 175848] [PubMed 6761136]
30. Vukich JA, Leef DL, Allen RC. Betaxolol in patients with coexistant chronic open angle glaucoma and pulmonary disease. Invest Ophthalmol. 1985; 26(Suppl):227.
31. DeSantis L, Chandler M. Cardiac beta blockade after ocular instillation of beta adrenergic blockers in alert cynomolgus monkeys: safety profile for betaxolol. Invest Ophthalmol. 1985; 26(Suppl):227.
32. Balnave K, Neill JD, Russell CJ et al. The duration of effect of SL 75212 on an exercise tachycardia. Br J Clin Pharmacol. 1980; 9:297P. [IDIS 115177] [PubMed 6102471]
33. Fillastre JP, Godin M, Cazor JL et al. Renal effects of betaxolol. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:183-93.
34. Friedmann JC. Safety evaluation of betaxolol. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:43-50.
35. Palminteri R, Kaik G. Time course of the bronchial response to salbutamol after placebo, betaxolol and propranolol. Eur J Clin Pharmacol. 1983; 24:741-5. [IDIS 173392] [PubMed 6136412]
36. Stroobandt R, Kesteloot H. Dose-related efficacy of betaxolol in patients with angina pectoris. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:257-60.
37. Kesteloot H, Missotten A, Coupez-Lopinot R et al. Effect of betaxolol on heart rate at rest and during exercise. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:155-9.
38. Saunders J, Gomeni R, Kilborn JR et al. A comparison between propranolol, practolol and betaxolol (SL 75212) on the circulatory and metabolic responses to insulin-induced hypoglycaemia. Eur J Clin Pharmacol. 1981; 21:177-84. [IDIS 142918] [PubMed 6119203]
39. Bianchetti G, Chauvin M, Giudicelli JF et al. Comparison of the β-adrenoceptor blocking properties and pharmacokinetics of SL 75212 and propranolol in man. Br J Clin Pharmacol. 1979; 8:407-8P.
40. Bianchetti G, Blatrix C, Gomeni R et al. Pharmacokinetics of the new β-adrenoceptor blocker SL 75212 in man after repeated oral administration. Br J Clin Pharmacol. 1979; 8:408P. [IDIS 105844] [PubMed 41560]
41. Bianchetti G, Gomeni R, Kilborn JR et al. Blood concentrations and pharmacodynamic effects of SL 75212, a new β-adrenoceptor antagonist, after oral and intravenous administration. Br J Clin Pharmacol. 1979; 8:403-4P.
42. Giudicelli JF, Richer C, Ganansia J et al. Betaxolol: β-adrenoceptor blocking effects and pharmacokinetics in man. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:89-99.
43. Balnave K, Neill JD, Russell CJ et al. Observations on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective β-adrenoceptor blocking drug. Br J Clin Pharmacol. 1981; 11:171-80. [IDIS 137812] [PubMed 6111331]
44. Palminteri R, Assael BM, Bianchetti G et al. Betaxolol kinetics in hypertensive children with normal and abnormal renal function. Clin Pharmacol Ther. 1984; 35:141-7. [IDIS 181904] [PubMed 6692644]
45. Morselli PL, Thiercelin JF, Padovani P et al. Comparative pharmacokinetics of several β-blockers in renal and hepatic insufficiency. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:233-41.
46. Ferrandes B, Durand A, Andrée-Fraisse J et al. Pharmacokinetics and metabolism of betaxolol in various animal species and man. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:51-64.
47. Thiercelin JF, Bianchetti G, Larribaud J et al. Effects of a meal and its composition on the bioavailability of betaxolol administered orally to healthy subjects. World Rev Nutr Diet. 1984; 43:183-6. [PubMed 6147938]
48. Warrington SJ, Taylor EA, Kilborn JR. Comparison of pharmacodynamic effects of betaxolol with atenolol, practolol, and propranolol given intravenously. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:109-22.
49. Warrington SJ, Turner P, Kilborn JR et al. Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new β-adrenoceptor antagonist after oral and intravenous administration. Br J Clin Pharmacol. 1980; 10:449-52. [IDIS 128199] [PubMed 6108127]
50. Weiss Y, Boutonnet G, Chenard A et al. Antihypertensive action and kinetics of a single daily dose of betaxolol. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:267-75.
51. Wax MB, Molinoff PB. Distribution and properties of beta-adrenergic receptors in human iris/ciliary body. Invest Ophthalmol Vis Sci. 1984; 25(Suppl):305.
52. Boger WP. Timolol: short term “escape” and long term “drift.” Ann Ophthalmol. 1979; 11:1239-42. Editorial.
53. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology. 1980; 87:447-50. [PubMed 7402590]
54. Williams T, Ginther WH. Hazard of ophthalmic timolol. N Engl J Med. 1982; 306:1485-6. [IDIS 150902] [PubMed 7078595]
55. McMahon CD, Shaffer RN, Hoskins HD Jr et al. Adverse effects experienced by patients taking timolol. Am J Ophthalmol. 1979; 88:736-8. [IDIS 104858] [PubMed 507146]
56. Harrison R. Betaxolol and timolol. Arch Ophthalmol. 1984; 102:1424. [PubMed 6148923]
57. Berry DP Jr, Shields MB, Van Buskirk M. Betaxolol and timolol. Arch Ophthalmol. 1984; 102:1424-5.
58. Jones FL Jr, Ekberg NL. Exacerbation of obstructive airway disease by timolol. JAMA. 1980; 244:2730. [IDIS 124860] [PubMed 7441859]
59. Ahmad S. Cardiopulmonary effects of timolol eyedrops. Lancet. 1979; 2:1028. [IDIS 105027] [PubMed 91770]
60. Zimmerman TJ, Leader BJ, Golob DS. Potential side effects of timolol therapy in the treatment of glaucoma. Ann Ophthalmol. 1981; 13:683-9. [PubMed 7020551]
61. Schoene RB, Martin TR, Charan NB et al. Timolol-induced bronchospasm in asthmatic bronchitis. JAMA. 1981; 245:1460-1. [IDIS 129427] [PubMed 7206150]
62. Anon. Additions to Timoptic contraindications. FDA Drug Bull. 1981; 11:1. [PubMed 7215728]
63. Taylor P. Anticholinesterase agents. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:110-27.
64. Remis LL, Epstein DL. Treatment of glaucoma. Ann Rev Med. 1984; 35:195-205. [PubMed 6426371]
65. Havener WH. Ocular pharmacology. 5th ed. St. Louis: The CV Mosby Company; 1983:18-43,261-417,635-72.
66. Henry JA, Mitchell SN. Effect of pH on human plasma protein binding of a series of β-adrenoceptor antagonists. Br J Clin Pharmacol. 1981; 11:119-20P.
67. Fraunfelder FT, Barker AF. Respiratory effects of timolol. N Engl J Med. 1984; 311:1441. [IDIS 192601] [PubMed 6493304]
68. Machin PJ, Hurst DN, Bradshaw RN et al. β1-Selective adrenoceptor antagonists. 2: 4-ether-linked phenoxypropanolamines. J Med Chem. 1983; 26:1570-6. [IDIS 177952] [PubMed 6138435]
69. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982; 26:207-18. [PubMed 7041308]
70. Smith LH. β-Adrenergic blocking agents. 15: 1-substituted ureidophenoxy-3-amino-2-propanols. J Med Chem. 1977; 20:705-8. [PubMed 16137]
71. Smith LH. β-Adrenergic blocking agents. 16: 1-(acylaminomethyl-, ureidomethyl-, and ureidoethylphenoxy)-3-amino-2-propanols. J Med Chem. 1977; 20:1254-8. [PubMed 20502]
72. Smith LH, Tucker H. β-Adrenergic blocking agents. 17: 1-phenoxy-3-phenoxyalkylamino-2-propanols and 1-alkoxyalkylamino-3-phenoxy-2-propanols. J Med Chem. 1977; 20:1653-6. [PubMed 22750]
73. Engel G. Subclasses of beta-adrenoceptors—a quantitative estimation of beta1- and beta2-adrenoceptors in guinea pigs and human lung. Postgrad Med J. 1981; 57(Suppl 1):77-83. [PubMed 6272254]
74. Allen RC. Betaxolol in the treatment of glaucoma: multi-clinic trials. Ophthalmology. 1984; 91(Suppl):142.
75. Langer SZ, Galzin AM. β-Adrenoceptors and noradrenergic neurotransmission: effects of betaxolol on the stimulation-evoked release of3H-norepinephrine in isolated rat atria and rabbit hypothalamic slices. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:21-30.
76. Söonksen PH, Brown PM, Saunders J et al. Metabolic and cardiovascular effects of betaxolol during hypoglycemia and exercise in normal volunteers. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:143-54.
77. Libersa C, Carrée A, Bertrand M et al. Study of the acute hemodynamic effects of betaxolol in noncomplicated essential hypertension. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:171-8.
78. Harrison DC, Buchbinder M, Schroeder JS. Acute hemodynamic effects of betaxolol. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:179-81.
79. Pathée M, Steimer C, Cazor JL et al. Dose-response study of betaxolol in hypertension. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:287-96.
80. Bianchetti G, Padovani P, Thiercelin JF et al. Pharmacokinetic studies on betaxolol—evaluation of the effects of age, hypertension, presence of food, and concomitant administration of hydrochlorothiazide on the disposition of the drug. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:123-31.
81. Barrett AM. Therapeutic applications of β-adrenoceptor antagonists. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:65-72.
82. Bergis SK. Long-term efficacy and safety of betaxolol and propranolol in hypertensive patients. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:353-7.
83. Beresford R, Heel RC. Betaxolol: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension. Drugs. 1986; 31:6-28. [IDIS 210401] [PubMed 2866947]
84. Gosselin RE, Smith RP, Hodge HC. Clinical toxicology of commercial products. 5th ed. Baltimore: Williams & Wilkins; 1984:I-6.
85. Gomeni R, Kilborn JR, Morselli PL et al. The action of the new β-adrenoceptor blocker SL 75212 on the metabolic response to insulin-induced hypoglycaemia in man. Br J Clin Pharmacol. 1979; 8:404P. [IDIS 105839] [PubMed 41557]
86. Davies IB, Larribaud J, Thiercelin JF et al. Betaxolol does not modify hypoglycaemic actions on glibenclamide or metformin in normal subjects. Br J Clin Pharmacol. 1984; 17:622P.
87. Merck Sharp & Dohme. Timoptic prescribing information. West Point, PA; 1985 Oct.
88. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs. 1981; 22:295-320. [IDIS 143257] [PubMed 7030708]
89. Brüugmann U, Blasini R. Comparative effects of long-acting beta-adrenergic receptor blockers with and without cardioselectivity: double-blind, randomized, cross-over and placebo-controlled study with betaxolol and nadolol. Circulation. 1983; 68(Suppl III):406. [IDIS 174045] [PubMed 6861316]
90. Saunders J, Prestwich SA, Avery AJ et al. The effect of non-selective and selective beta-1-blockade on the plasma potassium response to hypoglycaemia. Diabete Metab. 1981; 7:239-42. [PubMed 6120859]
91. Zimmerman TJ. Timolol maleate—a new glaucoma medication? Invest Ophthalmol Visual Sci. 1977; 16:687-8. Editorial.
92. Giudicelli JF, Chauvin M, Thuillez C et al. β-Adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL-75212) in man. Br J Clin Pharmacol. 1980; 10:41-9. [IDIS 116851] [PubMed 6104973]
93. Stewart RH, Kimbrough RL, Ward RL. Betaxolol vs timolol: a six-month double-blind comparison. Arch Ophthalmol. 1986; 104:46-8. [IDIS 209945] [PubMed 3510612]
94. Feghali JG, Kaufman PL. Decreased intraocular pressure in the hypertensive human eye with betaxolol, a β1-adrenergic antagonist. Am J Ophthalmol. 1985; 100:777-82. [IDIS 209309] [PubMed 2866715]
95. Spiritus EM, Casciari R. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol. 1985; 100:492-3. [IDIS 206433] [PubMed 4037047]
96. Schoene RB, Abuan T, Ward RL et al. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol. 1985; 100:493-4.
97. Dunn TL, Gerber MJ, Shen AS et al. Timolol-induced bronchospasm: utility of betaxolol as an alternative ocular hypotensive agent in patients with asthma. Clin Res. 1985; 33:20A.
98. Allen RC. Betaxolol in the treatment of glaucoma: multiclinic trials. Ophthalmology. 1984; 91:142.
